Naseema Gangat, MBBS

Articles

Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence

January 24th 2025

Panelists discuss how their treatment approach has evolved based on the efficacy and safety profiles from recent trials, how updated data align with or challenge NCCN Guidelines, and the clinical implications of real-world evidence. Dr Harrison explores treatment patterns, blood count control, and the decision to switch from hydroxyurea (HU) to ruxolitinib (RUX) therapy in polycythemia vera (PV).

Safety Considerations for PV Therapy

January 24th 2025

Panelists discuss the safety profiles of therapies for polycythemia vera (PV) and the safety considerations they take into account when determining which patients are best suited for these treatments.

Interferon Therapy in PV

January 17th 2025

Panelists discuss additional data supporting the use of alternative agents and treatment pathways for polycythemia vera (PV), including the role of ropeginterferon alfa-2b (Ropeg alfa-2b) based on findings from the PROUD-PV /CONTINUATION-PV studies.

JAK Inhibition in Polycythemia Vera: Treatment Updates

January 17th 2025

Panelists discuss the role of JAK inhibition in the treatment of polycythemia vera (PV), focusing on the latest efficacy data for ruxolitinib (RUX) from studies such as RUX vs best available therapy (BAT) in PV and the MAJIC-PV trial, highlighting its impact on treatment outcomes.

Cytoreductive Therapy in PV Treatment Paradigm

January 2nd 2025

Panelists discuss how cytoreductive therapy fits into the treatment paradigm for polycythemia vera (PV), highlighting key findings from the CYTO-PV study and its subanalysis, which inform their treatment decisions for patients with PV.

Initial Treatment Strategies for Polycythemia Vera

December 23rd 2024

Panelists discuss how they approach the evaluation and diagnosis of polycythemia vera (PV), including key clinical manifestations, and how they assess disease risk to determine initial treatment strategies based on NCCN guidelines, considering factors that differentiate low-risk from high-risk PV.